PLSE - NASDAQ
Pulse Biosciences, Inc.
$27.64
+11%Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
At a Glance
Live SnapshotPulse Biosciences, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Pulse Biosciences, Inc. Income Statement
PLSE • NASDAQ
| Pulse Biosciences, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||
350K | 0.0 | 0.0 | 700K | 1.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||
(1.6M) | (0.0) | (1.2M) | (11.9M) | (2M) | (1.1M) | (666K) | (665K) | (665K) | (665K) | (0.0) | (0.0) | |
-1.3M | 0.0 | -1.2M | -11.2M | -550K | -1.1M | -666K | -665K | -665K | -665K | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||||||
(75.7M) | (56.3M) | (42.4M) | (46.8M) | (62.5M) | (48.9M) | (48M) | (38M) | (25.8M) | (9.6M) | (4.5M) | (514.3K) | |
(32M) | (23.9M) | (15.8M) | (26M) | (33.8M) | (22.9M) | (22.3M) | (20M) | (15.5M) | (2.9M) | (1.2M) | (73.7K) | |
(44.7M) | (32.3M) | (27.8M) | (20.8M) | (28.6M) | (26.4M) | (25M) | (17.3M) | (9.6M) | (6M) | (2.6M) | (44.6K) | |
-76.9M | -56.3M | -43.6M | -58.1M | -63M | -50M | -48M | -38M | -25.8M | -9.6M | -4.5M | -308.6K | |
PRE-TAX INCOME | ||||||||||||
(0.0) | (0.0) | (1.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
4.2M | 2.7M | 1.4M | 0.0 | 0.0 | 114K | 983K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-1.1M | (0.0) | -1.2M | (0.0) | (0.0) | -430K | (666K) | -28K | (665K) | (665K) | (665.4K) | (0.0) | |
4.2M | 2.7M | 1.4M | -448K | -646K | 114K | 983K | 418K | 247K | 68K | 0.0 | -396K | |
-72.8M | -53.6M | -42.2M | -58.5M | -63.7M | -49.9M | -47M | -37.5M | -25.6M | -9.5M | -4.5M | -514.3K | |
NET INCOME | ||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -28K | (0.0) | -94K | -1.7M | -39.4K | |
-72.8M | -53.6M | -42.2M | -58.5M | -63.7M | -49.7M | -46M | -37.5M | -25.6M | -9.5M | -2.8M | -474.9K |
SEC Filings
PLSE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | May 11, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 23, 2026 | 2026 |
Related Guides
Continue your PLSE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.